Skip to main content

A game change in continuous biosensing: Molecularly engineered affinity-based nanoswitches for personal monitoring

Objective

Generic technology that allows continuous sensing of a wide range of biomolecular parameters could revolutionise patient monitoring and enable truly personalised therapy. Commercial sensors are available for continuous monitoring of glucose, but do not exist for other molecules that are important for monitoring disease status and treatment effect, including peptides, proteins, hormones, and drugs. The ambition of CONSENSE is to provide a game change in continuous biomolecular sensing by combining advanced molecular engineering with tailored optical detection technologies to yield generic, affinity-based biosensing technologies. CONSENSE will focus on the construction of biomolecular nanoswitches that translate molecular binding into robust and well-defined conformational changes at length scales that can be detected by selected optical detection methods, providing unique possibilities to distinguish between specific and nonspecific binding. While the applications for this new technology are wide and varied, within CONSENSE we will focus on immune monitoring in critical care settings, where patients have an urgent need for continuous monitoring related to inflammation and immunotherapy. CONSENSE brings together internationally leading pioneers in biomolecular switch engineering with research groups that have an excellent track record in biosensor development using advanced optical approaches, including two high-tech companies that have spun out from these groups. The consortium is completed by a strong network of partner industries and organisations, including four large medical technology companies, clinical experts, and six SMEs providing specific technological expertise and training. The consortium will provide exceptional training to 15 ESRs, allowing them to develop professionally and perform world-class research that will fundamentally advance the field of continuous biomolecular monitoring for healthcare.

Field of science

  • /engineering and technology/environmental biotechnology/biosensing

Call for proposal

H2020-MSCA-ITN-2020
See other projects for this call

Funding Scheme

MSCA-ITN-ETN - European Training Networks

Coordinator

TECHNISCHE UNIVERSITEIT EINDHOVEN
Address
Groene Loper 3
5612 AE Eindhoven
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 796 859,64

Participants (8)

AARHUS UNIVERSITET
Denmark
EU contribution
€ 595 044
Address
Nordre Ringgade 1
8000 Aarhus C
Activity type
Higher or Secondary Education Establishments
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Switzerland
EU contribution
€ 562 553,28
Address
Batiment Ce 3316 Station 1
1015 Lausanne
Activity type
Higher or Secondary Education Establishments
WEIZMANN INSTITUTE OF SCIENCE
Israel
EU contribution
€ 527 001,84
Address
Herzl Street 234
7610001 Rehovot
Activity type
Higher or Secondary Education Establishments
KATHOLIEKE UNIVERSITEIT LEUVEN
Belgium
EU contribution
€ 256 320
Address
Oude Markt 13
3000 Leuven
Activity type
Higher or Secondary Education Establishments
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Germany
EU contribution
€ 505 576,80
Address
Hofgartenstrasse 8
80539 Muenchen
Activity type
Research Organisations
STICHTING KATHOLIEKE UNIVERSITEIT
Netherlands
EU contribution
€ 265 619,88
Address
Geert Grooteplein Noord 9
6525 EZ Nijmegen
Activity type
Higher or Secondary Education Establishments
FOX BIOSYSTEMS NV
Belgium
EU contribution
€ 256 320
Address
Agoralaan Abis
3590 Diepenbeek
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
HELIA BIOMONITORING BV
Netherlands
EU contribution
€ 265 619,88
Address
Den Dolech 2, Mmp 0.42
5612 AZ Eindhoven
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)